Shares of Abiomed, Inc. (ABMD) are up $4.46, or 17.59%, at $29.81, in late trading, after the company today reported fiscal Q2 revenue and earnings that beat Wall Street’s expectations, and forecast full year revenue higher as well. Revenue in Q2 rose 17.2%, year-over-year, to $51.9 million versus $49.99 million forecasts, yielding EPS of $0.09 […]
View the full post at: Trader’s Buzz: Abiomed (ABMD), Myos Corp (MYOS), Changyou.com (CYOU), TrovaGene (TROV), Vitae Pharmaceuticals (VTAE)